Scientists design gene delivery systems for cells in the brain and
NIH-funded breakthrough could enable targeted therapies for many neurological disorders.
Related Articles
Smoking cessation pill may help youth quit vaping
Teens and young adults who took a smoking cessation drug called varenicline were more likely to quit vaping nicotine than those who got a placebo…
ASCO/ESMO Joint Session at ASCO25 Will Highlight Key Issues in Biomarker-Driven Therapeutics
The ASCO/ESMO Joint Session at the ASCO Annual Meeting will explore emerging trends and clinical implications of integrating biomarker-driven therapies into clinical care. The session…
The Most Clinically Relevant Science in Oncology Will Be Presented at ASCO25 – OncoDaily
The Most Clinically Relevant Science in Oncology Will Be Presented at ASCO25 / ASCO, ASCO25, cancer, OncoDaily, Oncology, Science in Oncology
ASCO/ESMO Joint Session at ASCO25 Will Highlight Key Issues in Biomarker-Driven Therapeutics
The ASCO/ESMO Joint Session at the ASCO Annual Meeting will explore emerging trends and clinical implications of integrating biomarker-driven therapies into clinical care. The session…
From Dr Google to AI: Tech Improving But Moravec’s Paradox Still Matters
Despite advanced algorithms, AI lacks certain human abilities. Arturo Loaiza-Bonilla MD, MSEd, explores Moravec’s paradox to highlight what the tech still can’t replace.
Scientists design gene delivery systems for cells in the brain and
NIH-funded breakthrough could enable targeted therapies for many neurological disorders.
Scientists design gene delivery systems for cells in the brain and
NIH-funded breakthrough could enable targeted therapies for many neurological disorders.
Involuntary responses reflect severity of tinnitus symptoms
By analyzing subtle facial movements, researchers found ways to objectively measure the severity of tinnitus and sound sensitivity disorder symptoms.
ASCO/ESMO Joint Session at ASCO25 Will Highlight Key Issues in Biomarker-Driven Therapeutics
The ASCO/ESMO Joint Session at the ASCO Annual Meeting will explore emerging trends and clinical implications of integrating biomarker-driven therapies into clinical care. The session…
Regeneron plans to buy 23andMe for $256M
Regeneron is acquiring 23andMe through a court-supervised sale, following 23andMe’s bankruptcy filing and recent struggles.